



Cyto Pulse Sciences, Inc.

Glen Burnie, MD, USA
Voice: 410-787-1890
www.cytopulse.com

Contact: Tim Hurd

FOR IMMEDIATE RELEASE

February 2, 2008

Cyto Pulse Sciences and Aldevron Announce Intradermal Electroporation Delivery Licensing Agreement

GLEN BURNIE, Md., January 30, 2008 -- Cyto Pulse Sciences, the leading developer of tolerable, electric field based, intradermal DNA Vaccine delivery, today announced a licensing agreement with Aldevron, LLC to use Cyto Pulse's DNA Vaccine delivery technology. This agreement follows studies conducted at Aldevron that showed comparable efficacy at significantly lower dosage levels than standard intramuscular electroporation delivery.

"Aldevron is very pleased with our initial results and look forward to using the technology for future immunization studies. Furthermore, this license will allow Aldevron's clients to utilize the Cyto Pulse technology through our contract service," said Michael Chambers, Aldevron CEO.

"Cyto Pulse is pleased to enter into this agreement with Aldevron. This is yet another case of the Cyto Pulse intradermal DNA vaccine delivery technology providing superior results," said Richard Walters, Cyto Pulse CEO.

Aldevron based in Fargo, ND, works with research groups and biopharmaceutical companies to manufacture high quality DNA, proteins and antibodies. These biological molecules are used for preclinical, clinical, diagnostic and agricultural applications. Aldevron is also engaged in collaborative vaccine research and is co-developing a novel treatment for late-stage lung cancer. The company has facilities in Fargo, ND and Freiburg, Germany. Visit Aldevron's website for more information at <http://www.aldevron.com>.

Cyto Pulse Sciences, Inc. is a biomedical device and treatment development company offering innovative technology DNA and RNA vaccine delivery, antibody discovery, and polynucleotide vaccine production. The company was founded in 1996 to develop clinical and commercial electric field based systems, making possible gene therapy, immunotherapeutic and prophylactic treatments unattainable by chemical or viral vectors. Cyto Pulse technology enables cellular material transfers and cell fusion with a high degree of safety, repeatability and efficiency for clinical use and commercial production. Additional information on Cyto Pulse Sciences, Inc. is available at the company's website, <http://www.cytopulse.com>.

###